These findings emphasize the rationale for combining anti-CD73 and anti-PD-L1 treatments as a promising therapeutic strategy for EGFR-mutated NSCLC, implicating an integral role for heightened T-cell activity in therapeutic response (144). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.